Targacept, Inc. (TRGT) Reports First Quarter 2013 Financial Results
5/7/2013 8:13:14 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.
Targacept reported a net loss of $8.1 million for the first quarter of 2013, compared to net income of $2.3 million for the first quarter of 2012. As of March 31, 2013, cash and investments in marketable securities totaled $175.1 million.
Help employers find you! Check out all the jobs and post your resume.
comments powered by